# Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer

> **NCT03484221** · PHASE2 · UNKNOWN · sponsor: **China Medical University, China** · enrollment: 30 (estimated)

## Conditions studied

- Rectal Neoplasms
- Drug Therapy
- Radiation

## Interventions

- **DRUG:** FOLFOXIRI
- **RADIATION:** Short-Course Radiation Therapy(5Gy*5)
- **DRUG:** XELOX

## Key facts

- **NCT ID:** NCT03484221
- **Lead sponsor:** China Medical University, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-01
- **Primary completion:** 2021-10-01
- **Final completion:** 2022-04-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03484221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03484221, "Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03484221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*